FAQ on Quantum BioPharma Ltd.'s Opposition to Motion to Dismiss in $700 Million Market Manipulation Lawsuit
Summary
What is Quantum BioPharma Ltd. alleging in its lawsuit?
Quantum BioPharma Ltd. alleges that CIBC World Markets and RBC Dominion Securities, among others, engaged in market manipulation through ‘spoofing’ between January 1, 2020, and August 15, 2024, violating federal securities laws and artificially depressing its stock price.
How much is Quantum BioPharma seeking in damages?
Quantum BioPharma is seeking more than $700 million in damages for the alleged market manipulation that affected its stock price.
Who is representing Quantum BioPharma in this lawsuit?
The case is being pursued on a contingency basis by Christian Attar and Freedman Normand Friedland LLP.
What is ‘spoofing’ in the context of this lawsuit?
Spoofing refers to the alleged practice of placing fake orders to buy or sell stocks to create a false impression of demand or supply, thereby manipulating the market price, which Quantum BioPharma claims was done hundreds of times to depress its stock.
What is the significance of Quantum BioPharma’s stock once trading above $460 per share?
The mention of Quantum BioPharma’s stock once trading above $460 per share highlights the extent of the alleged manipulation’s impact, showing a significant decline from its previous value due to the spoofing activities.
Is Quantum BioPharma open to resolving the lawsuit outside of court?
Yes, Quantum BioPharma remains open to a potential resolution and believes additional banks or brokers may be involved in the alleged market manipulation.
Where can I find more information about Quantum BioPharma Ltd.?
More information about Quantum BioPharma Ltd. is available in the company’s newsroom at https://ibn.fm/QNTM.
What is Quantum BioPharma’s focus as a biopharmaceutical company?
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.
What is Lucid-MS, and why is it significant?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models, representing a significant potential advancement in treatment.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 134567